This study is currently not recruiting participants.

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Study on Investigational Medication for Pancreatic Cancer

Not Recruiting
18 years - 90 years
All
Phase N/A

Brief description of study.

The purpose of this study is is to test the effectiveness of a new drug to treat pancreatic cancer.

Detailed description of study

The purpose of this study is is to test the effectiveness of a new drug to treat pancreatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pancreatic Cancer
  • Age: 18 years - 90 years
  • Gender: All

This study investigates the effectiveness of an investigational medication for treating pancreatic cancer. Pancreatic cancer is a disease where cancerous cells form in the tissues of the pancreas, an organ that helps with digestion and blood sugar regulation.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.

  • Who can participate: Individuals aged 18 and older diagnosed with pancreatic cancer may participate. Key eligibility includes no prior treatment for pancreatic cancer and adequate organ function.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1310585054

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team